Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study.
暂无分享,去创建一个
A. Lluch | S. González | R. Andrés | N. Ribelles | E. Carrasco | M. Ramos | L. Calvo | M. Casas | Á. Rodríguez-Lescure | Miguel Martín | A. Barnadas | P. Sánchez‐Rovira | C. Jara | E. Adrover | J. R. De la Haba-Rodríguez | A. Plazaola | A. Santaballa | N. Martínez-Jáñez | M. Ruíz Borrego | M. Muñoz-Mateu | J. López-Vega | C. Mendiola Fernández | C. Rodríguez | A. Ballesteros | S. Del Barco Berrón | E. Martínez de Dueñas | J. Baena-Cañada | M. Margeli Vila | A. Ruiz Simón | Jose Manuel López-Vega | María del Carmen Cámara | S. del Barco Berrón | P. Sánchez-Rovira | N. Martínez-Jañez
[1] G. Romieu,et al. Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] N. Robert,et al. Capecitabine monotherapy: review of studies in first-line HER-2-negative metastatic breast cancer. , 2012, The oncologist.
[3] F. Holmes,et al. Abstract S4-2: First Efficacy Results of a Randomized, Open-Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without Capecitabine, in High-Risk Early Breast Cancer , 2010 .
[4] Edith A Perez,et al. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] Arrate Plazaola,et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. , 2008, Journal of the National Cancer Institute.
[6] R. Gelber,et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. , 2008, Journal of the National Cancer Institute.
[7] C. Thompson. FDA approves new breast cancer treatment. , 2007, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[8] D. Ghersi,et al. Taxanes for adjuvant treatment of early breast cancer. , 2007, The Cochrane database of systematic reviews.
[9] T. Delozier,et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] M. Milella,et al. Benefit of taxanes as adjuvant chemotherapy for early breast cancer , 2006, Cancer.
[11] Y Wang,et al. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.
[12] Richard L Schilsky,et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] C. Twelves,et al. Moving forward with capecitabine: a glimpse of the future. , 2002, The oncologist.
[14] A. Munkarah,et al. Alternate dosing schedules for topotecan in the treatment of recurrent ovarian cancer. , 2002, The oncologist.
[15] Y. Tanaka,et al. Schedule dependency of antitumor activity in combination therapy with capecitabine/5'-deoxy-5-fluorouridine and docetaxel in breast cancer models. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[16] H. Ishitsuka,et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. , 1998, European journal of cancer.
[17] H. Ishitsuka,et al. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[18] P. O'Brien,et al. A multiple testing procedure for clinical trials. , 1979, Biometrics.
[19] J. Hainsworth,et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. , 2013, The Lancet. Oncology.
[20] V. Kataja,et al. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Xueri Li,et al. Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients:The FNCLCC PACS 01 Trial , 2009 .
[22] C. Criscitiello,et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] V. Noronha,et al. Adjuvant docetaxel for node-positive breast cancer. , 2005, The New England journal of medicine.